Cardiology Search
Cardiology Cardiology
tachycardia
TACHYCARDIA

Tachycardia or tachyarrhythmia is used to describe the presence of cardiac rhythm abnormality in states when cardiac rate is increased to >100 bpm.

Divided into supraventricular and ventricular tachycardia.

Signs and symptoms related to rapid heart rate are altered sensorium, angina, shortness of breath, myocardial infarction, hypotension and other signs of shock (eg cold clammy skin, low urine output), heart failure or pulmonary congestion.

Tachycardia Drug Information

Drug Information

Indication: DVT & pulmonary embolism (PE). Prevention of stroke & systemic embolism in adult patients w/ non-valvu...

Indication: Control of tonic-clonic (grand mal) status epilepticus. Prevention & treatment of seizures during or follo...

Dosage: HTN 50-100 mg daily as single dose. Arrhythmia Oral maintenance: 50-100 mg daily as single dose. Angina 50 mg

Indication: HTN; angina pectoris; MI. Disturbances of cardiac rhythm including supraventricular tachycardia. Functional he...

Indication: Adult patients suffering from MI (few days until <35 days), ischaemic stroke (7 days until <6 mth) or es...

Indication: Prevention of atherothrombotic events in MI (from a few days until <35 days), ischaemic stroke (7 days unti...

Indication: Prevention of artherothrombotic events eg, recent MI, stroke, established peripheral arterial disease; acute c...

Indication: Acute hypomagnesaemia. Prevention of hypomagnesaemia in patients receiving TPN. Prevention & treatment of ...

Indication: Control of generalised tonic-clonic (grand mal) epilepsy & psychomotor seizures.

Indication: Control of tonic-clonic (grand mal) status epilepticus. Prevention & treatment of seizures occurring durin...

1  /  7
1  /  7
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Lower cholesterol targets after stroke may reduce subsequent major vascular events
29 Mar 2020
Targeting a low-density lipoprotein cholesterol level <70 mg/dL following an ischaemic stroke of atherosclerotic origin helps to avoid one in four subsequent major vascular events without increasing the risk of intracranial haemorrhage over about 5 years of follow-up, according to data from the Treat Stroke to Target trial.
Rhythm vs rate control in AF: A win finally?
Pearl Toh, 12 Sep 2020
Early initiation of rhythm-control therapy led to a significantly reduced risk of major adverse cardiovascular (CV) outcomes compared with usual care (typically rate control) in patients with newly diagnosed atrial fibrillation (AF) at risk of stroke, reveals the EAST-AFNET 4* trial presented at ESC 2020.
Can coronary plaque EVAPORATE with prescription-grade EPA?
Audrey Abella, 16 Sep 2020
The final results of EVAPORATE* reinforce the plaque-regressing potential of icosapent ethyl (IPE) in patients on statins for elevated triglycerides.
High-intensity statin regimens becoming more common
01 Feb 2020
High-intensity statin therapy appears to be seeing increased use in patients with acute coronary syndrome and leads to better lipid control, according to a recent Thailand study.